MIRAPEX ER
PeakNDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2010
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRAPEX ER is an extended-release oral tablet formulation of pramipexole, a dopamine agonist indicated for movement disorders. The drug works by stimulating dopamine receptors in the central nervous system. Specific indications are not disclosed in available data.
Peak3.2 years to LOE
Product is in peak commercial phase with high competitive pressure (score: 8/10), indicating mature market dynamics and established cross-functional team infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on MIRAPEX ER at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.